Ing Groep Nv Regeneron Pharmaceuticals, Inc. Transaction History

Ing Groep Nv

$16.5 Billion
Q3 2024

A detailed history of Ing Groep Nv transactions in Regeneron Pharmaceuticals, Inc. stock. As of the latest transaction made, Ing Groep Nv holds 21,761 shares of REGN stock, worth $16.5 Million. This represents 0.14% of its overall portfolio holdings.

Number of Shares

21,761

Previous 5,060 330.06%

Holding current value

$16.5 Million

Previous $5.32 Million 330.16%

% of portfolio

0.14%

Previous 0.03%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 06, 2024	BUY	$1024.09 - $1201.76 $17.1 Million - $20.1 Million	16,701 Added 330.06%	21,761 $22.9 Million
Q2 2024 Aug 13, 2024	SELL	$883.2 - $1071.19 $19.6 Million - $23.8 Million	-22,247 Reduced 81.47%	5,060 $5.32 Million
Q1 2024 May 10, 2024	SELL	$902.69 - $993.35 $906,300 - $997,323	-1,004 Reduced 3.55%	27,307 $26.3 Million
Q4 2023 Feb 08, 2024	SELL	$775.18 - $881.7 $5.8 Million - $6.6 Million	-7,484 Reduced 20.91%	28,311 $24.9 Million
Q3 2023 Oct 27, 2023	BUY	$692.45 - $844.37 $2.11 Million - $2.58 Million	3,052 Added 9.32%	35,795 $29.5 Million
Q2 2023 Aug 07, 2023	SELL	$700.03 - $830.35 $63,702 - $75,561	-91 Reduced 0.28%	32,743 $23.5 Million
Q1 2023 May 09, 2023	BUY	$680.49 - $826.97 $3.51 Million - $4.26 Million	5,151 Added 18.61%	32,834 $27 Million
Q4 2022 Feb 10, 2023	BUY	$705.89 - $766.39 $19.5 Million - $21.2 Million	27,683 New	27,683 $20 Million
Q2 2022 Aug 08, 2022	SELL	$548.35 - $738.84 $15.1 Million - $20.3 Million	-27,500 Reduced 50.8%	26,631 $15.7 Million
Q1 2022 May 13, 2022	BUY	$595.12 - $698.43 $2.88 Million - $3.38 Million	4,841 Added 9.82%	54,131 $37.8 Million
Q4 2021 Feb 11, 2022	BUY	$543.48 - $670.97 $21 Million - $25.9 Million	38,616 Added 361.78%	49,290 $31.1 Million
Q3 2021 Nov 02, 2021	BUY	$574.03 - $680.96 $131,452 - $155,939	229 Added 2.19%	10,674 $6.46 Million
Q2 2021 Aug 13, 2021	BUY	$472.8 - $558.54 $4.94 Million - $5.83 Million	10,445 New	10,445 $5.83 Million
Q1 2021 May 12, 2021	SELL	$446.73 - $548.2 $3.11 Million - $3.81 Million	-6,955 Closed	0 $0
Q4 2020 Feb 11, 2021	BUY	$478.3 - $607.98 $2.22 Million - $2.82 Million	4,641 Added 200.56%	6,955 $3.36 Million
Q3 2020 Nov 12, 2020	BUY	$544.75 - $658.21 $795,879 - $961,644	1,461 Added 171.28%	2,314 $1.3 Million
Q2 2020 Aug 13, 2020	SELL	$493.32 - $643.92 $300,431 - $392,147	-609 Reduced 41.66%	853 $532,000
Q1 2020 May 06, 2020	BUY	$336.18 - $494.43 $491,495 - $722,856	1,462 New	1,462 $714,000
Q4 2019 Feb 10, 2020	SELL	$274.13 - $376.51 $1.37 Million - $1.88 Million	-4,988 Closed	0 $0
Q3 2019 Nov 08, 2019	SELL	$273.46 - $318.39 $6.22 Million - $7.24 Million	-22,754 Reduced 82.02%	4,988 $1.38 Million
Q2 2019 Aug 12, 2019	BUY	$299.6 - $414.82 $8.31 Million - $11.5 Million	27,742 New	27,742 $8.68 Million
Q1 2019 May 13, 2019	SELL	$372.08 - $439.57 $7.48 Million - $8.84 Million	-20,115 Closed	0 $0
Q4 2018 Feb 13, 2019	BUY	$335.82 - $403.04 $5.51 Million - $6.61 Million	16,395 Added 440.73%	20,115 $7.51 Million
Q3 2018 Nov 06, 2018	BUY	$351.14 - $408.51 $1.31 Million - $1.52 Million	3,720 New	3,720 $1.5 Million
Q2 2018 Aug 10, 2018	SELL	$284.6 - $344.99 $2.32 Million - $2.81 Million	-8,142 Closed	0 $0
Q1 2018 May 07, 2018	BUY	$315.82 - $393.78 $2.57 Million - $3.21 Million	8,142 New	8,142 $2.8 Million
Q4 2017 Feb 06, 2018	SELL	$358.63 - $469.95 $4.83 Million - $6.33 Million	-13,470 Closed	0 $0
Q3 2017 Nov 08, 2017	BUY	$431.38 - $504.0 $5.81 Million - $6.79 Million	13,470	13,470 $6.02 Million

Others Institutions Holding REGN

# of Institutions

1,529

Shares Held

84.1M

Call Options Held

1.22M

Put Options Held

1.51M

View Full List

About REGENERON PHARMACEUTICALS, INC.

Ticker REGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 107,190,000
Market Cap $81.1B
Description
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...

More about REGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ing Groep Nv, based on Form 13F filings with the SEC.

News

Stay updated on Ing Groep Nv with notifications on news.

Account